Fever, travellers and outbreak response

Fever requires clinical context

Assess observations, perfusion, mental state, respiratory function and localising symptoms. Sepsis or organ dysfunction needs urgent treatment regardless of the exact temperature. Ask about immune suppression, recent surgery/devices, medicines, animals, sexual exposures and travel. Fever can also reflect inflammatory disease, malignancy or a drug reaction. Persistent night sweats, weight loss or focal findings warrant targeted investigation. Avoid describing every unexplained fever as a viral illness simply because the first examination is nonspecific.

In a patient receiving chemotherapy or otherwise at risk of neutropenia, fever can be an emergency with limited local signs. Obtain urgent assessment, cultures and appropriate empirical treatment under the local neutropenic-sepsis pathway. Do not wait for a high white count or visible pus. Antimicrobial selection depends on host risks, probable source, local resistance and allergy/renal function. Cultures should precede treatment when this does not significantly delay rescue care. Repeat examination and source control remain important after antibiotics have begun.

Returning travellers

Record destinations, dates, transit, activities, food/water, insects, freshwater, animals, healthcare contact and vaccination/prophylaxis. The country name alone does not define risk; rural exposure, season and incubation intervals matter. Malaria is considered urgently after travel to an endemic region, including in someone who took prophylaxis. Obtain appropriate blood films/rapid testing and specialist advice. A single initial negative result may not settle a strong suspicion, requiring repeat assessment/testing through the diagnostic pathway. Falciparum malaria can deteriorate rapidly.

Dengue may cause fever, headache, myalgia and cytopenias, with warning signs such as abdominal pain, bleeding or deterioration as fever settles. Assess fluids and haematocrit/platelets in context; avoid indiscriminate aggressive fluids or NSAIDs when bleeding risk is relevant. Enteric fever, rickettsial disease, leptospirosis, viral hepatitis and other infections are considered according to exposure and timing. Travel-associated diarrhoea requires hydration and severity assessment, with tests/antibiotics selected for clinical risk. Bloody diarrhoea does not automatically justify any antibiotic without considering the pathogen and potential harm.

Before departure

Assess itinerary, duration, accommodation, planned activities, age, pregnancy, immune status and chronic illness well before travel. Review routine and destination-specific vaccination, malaria prevention, mosquito avoidance, safe food/water, sexual health and access to medical care. Check current country recommendations and entry requirements rather than relying on a memorised permanent list. TGA approval, personal recommendation and public funding are different issues. Some live vaccines are unsuitable in pregnancy or substantial immunosuppression; seek specialist advice where needed.

Explain medicine supply, documentation, storage, time-zone dosing and contingency plans. Discuss altitude, heat, diving or remote-area risks where relevant. Travellers visiting friends/relatives can underestimate infectious risks and deserve the same assessment as tourists. Address costs and access realistically. A pre-travel visit also offers an opportunity for injury prevention, road safety and insurance/evacuation planning. Advice should be specific to the trip rather than a generic brochure substituted for clinical assessment.

Isolation, notification and outbreaks

Suspected measles, TB or another transmissible condition needs appropriate infection-control precautions while assessment proceeds. Phone ahead before sending a potentially infectious patient into a crowded waiting room. Notification duties and deadlines arise from state/territory law; clinicians contact the relevant health authority, which contributes to national surveillance. Do not wait for definitive laboratory confirmation when the local suspected-case threshold requires action. Notification is separate from treatment, isolation and contact management, all of which can be urgent.

An outbreak investigation establishes a working case definition, verifies diagnosis, identifies cases and describes time, place and person. Develop and test exposure hypotheses, coordinate specimens and institute control measures as evidence permits. Do not wait for a finished epidemiological study before reducing a clear hazard. Public-health teams direct contact tracing, prophylaxis, vaccination or exclusion criteria. Confidentiality still matters: disclose necessary information through lawful channels, not an identifiable patient list circulated informally to an entire workplace.

Applied scenarios

A febrile traveller returning from a malaria-endemic area needs urgent malaria testing/assessment even after prophylaxis. A coughing febrile patient with a compatible measles exposure should not sit unannounced in a shared waiting room. Several patients with diarrhoea after one event warrant public-health coordination and exposure assessment, while each receives individual clinical care. A patient with fever after chemotherapy needs urgent neutropenic-sepsis assessment rather than a routine viral diagnosis. These decisions combine clinical urgency with population protection.

Explain the reason for isolation and notification, check the person's ability to comply and arrange food, housing or other support when necessary. Stigma can reduce disclosure and attendance; use respectful communication about travel, migration and exposure. Document advice, contacts and result ownership, including follow-up of initially negative tests when suspicion remains. Provide clear escalation signs for deterioration, bleeding, confusion or inability to maintain fluids.

Australian CDC malaria information and malaria laboratory case definition.

Review checkpoints

• Consider malaria after relevant travel even when prophylaxis was taken.
• Strong malaria suspicion can require repeat blood films after an initial negative result.
• Notify the relevant public-health service using local disease-specific requirements.